Kinder Morgan Inc vs Vaxcyte Inc. Common Stock — how do they compare? Kinder Morgan Inc trades at $33.37 (market cap $74.44B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Kinder Morgan Inc is far larger — about 7.1× Vaxcyte Inc. Common Stock's market cap, and Kinder Morgan Inc pays a 3.53% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KMI | PCVX | |
|---|---|---|
Market Cap | $74.44B | $10.51B |
Volume | 10,771,998 | 2,644,694 |
Sector | Energy | Health |
52-Week High | $34.31 | $73.82 |
52-Week Low | $25.84 | $40.32 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.49B | $9.14B |
Dividend Yield | 3.53% | — |
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains solid fundamentals with $16.94B revenue, 19.31% net margin, and a $6B-$7B growth pipeline. Analyst consensus is mixed with 47% buy ratings and a $37.20 price target, while technical indicators show support at $33 and resistance at $34.
KMI offers income investors a compelling dividend yield with growth potential from natural gas infrastructure demand, though elevated debt levels and energy market volatility present risks. The stock's current valuation at 21.57 P/E appears reasonable given earnings growth trajectory and stable fee-based revenue model.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →